When to Stop Daratumumab?

Darzalex is administered until signs of progression of multiple myeloma (MM) occur, or side effects become intolerable. Treatment durations of up to 25 months have been reported in clinical trials (range 0.1 month to 40.44 months). Research suggests people with IgG MM may be more responsive to Darzalex treatment.

How long is Daratumumab effective?

Darzalex is often given with other medications to treat multiple myeloma, and the duration of treatment can depend on the tolerability of the whole regimen, not just Darzalex. Clinical trials have reported treatment durations of up to 25.3 months (range 0.1 month to 40.44 months).

What is the half life of Daratumumab?

The mean (SD) estimated terminal half-life associated with linear clearance is approximately 18 (9) days. Population PK analyses indicated that the central volume of distribution and clearance of daratumumab increase with increasing body weight, supporting the body weight-based dosing regimen.